Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371719 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
A Phase 2 study of Recurrent Prostate Carcinoma and Stage IV Prostate Adenocarcinoma AJCC v7, sponsored by NRG Oncology.
- Active
- Registry status
- Phase 2
- Development phase
- 324
- Enrollment target
- 20
- Study locations
NCT03371719 is a Phase 2 study of Recurrent Prostate Carcinoma and Stage IV Prostate Adenocarcinoma AJCC v7 that is active but no longer recruiting, run by NRG Oncology. The registered enrollment target is 324 participants, above the 154-participant average among 29 other Recurrent Prostate Carcinoma trials with a reported enrollment target (110% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT03371719, a Phase 2 study of Recurrent Prostate Carcinoma and Stage IV Prostate Adenocarcinoma AJCC v7, is active but no longer recruiting, sponsored by NRG Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 324 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with prostate cancer that has come back (recurrent). Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and apalutamide may work better at treating prostate cancer compared to radiation therapy alone.
Conditions Studied
Interventions
- RADIATION External Beam Radiation Therapy
- DRUG Apalutamide
- OTHER Placebo Administration
Study Locations (20)
California
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Marin General Hospital - Greenbrae
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- Sutter Cancer Centers Radiation Oncology Services-Roseville - Roseville
- Sutter Medical Center Sacramento - Sacramento
- University of California Davis Comprehensive Cancer Center - Sacramento
- Gene Upshaw Memorial Tahoe Forest Cancer Center - Truckee
- Sutter Solano Medical Center/Cancer Center - Vallejo
Colorado
- UCHealth University of Colorado Hospital - Aurora
- Penrose-Saint Francis Healthcare - Colorado Springs
- UCHealth Memorial Hospital Central - Colorado Springs
- Memorial Hospital North - Colorado Springs
- Poudre Valley Hospital - Fort Collins
Arizona
- Arizona Center for Cancer Care - Gilbert - Gilbert
- Arizona Center for Cancer Care-Peoria - Peoria
- Arizona Center for Cancer Care - Scottsdale - Scottsdale
- Arizona Center for Cancer Care-Surprise - Surprise
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2018-06-20 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03371719
The ClinicalTrials.gov registry entry for NCT03371719 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 154-participant average among 29 other Recurrent Prostate Carcinoma trials with a reported enrollment target (110% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which External Beam Radiation Therapy is the first listed.
NCT03371719 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT03371719 about?
NCT03371719 is a clinical study titled "Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial". This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with prostate cancer that has come back (recurrent). Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. D...
What is the current status of trial NCT03371719?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 324 participants. The study started on 2018-06-20. Estimated completion is 2026-03-01.
What conditions does trial NCT03371719 study?
This clinical trial studies the following conditions: Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7.
What interventions are being tested in trial NCT03371719?
The interventions under investigation include: External Beam Radiation Therapy (RADIATION), Apalutamide (DRUG), Placebo Administration (OTHER).
Who is sponsoring clinical trial NCT03371719?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03371719 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
RECRUITING · Phase 2
-
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
RECRUITING · Phase 2
-
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
ACTIVE NOT RECRUITING · Phase 2
-
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Recurrent Prostate Carcinoma
All registered trials for this condition
Stage IV Prostate Adenocarcinoma AJCC v7
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.